JP2021522347A5 - - Google Patents

Info

Publication number
JP2021522347A5
JP2021522347A5 JP2021510507A JP2021510507A JP2021522347A5 JP 2021522347 A5 JP2021522347 A5 JP 2021522347A5 JP 2021510507 A JP2021510507 A JP 2021510507A JP 2021510507 A JP2021510507 A JP 2021510507A JP 2021522347 A5 JP2021522347 A5 JP 2021522347A5
Authority
JP
Japan
Prior art keywords
polypeptide chain
lag
acid sequence
seq
amino acid
Prior art date
Application number
JP2021510507A
Other languages
English (en)
Japanese (ja)
Other versions
JP7368453B2 (ja
JPWO2019210848A5 (https=
JP2021522347A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2019/085164 external-priority patent/WO2019210848A1/en
Publication of JP2021522347A publication Critical patent/JP2021522347A/ja
Publication of JPWO2019210848A5 publication Critical patent/JPWO2019210848A5/ja
Publication of JP2021522347A5 publication Critical patent/JP2021522347A5/ja
Application granted granted Critical
Publication of JP7368453B2 publication Critical patent/JP7368453B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021510507A 2018-05-03 2019-04-30 Pd-1およびlag-3に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質 Active JP7368453B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/085468 2018-05-03
CN2018085468 2018-05-03
PCT/CN2019/085164 WO2019210848A1 (en) 2018-05-03 2019-04-30 High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom

Publications (4)

Publication Number Publication Date
JP2021522347A JP2021522347A (ja) 2021-08-30
JPWO2019210848A5 JPWO2019210848A5 (https=) 2022-04-22
JP2021522347A5 true JP2021522347A5 (https=) 2022-04-22
JP7368453B2 JP7368453B2 (ja) 2023-10-24

Family

ID=68386276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021510507A Active JP7368453B2 (ja) 2018-05-03 2019-04-30 Pd-1およびlag-3に対する高親和性抗体ならびにそれらから作製された二重特異性結合タンパク質

Country Status (12)

Country Link
US (1) US12060425B2 (https=)
EP (1) EP3788079A4 (https=)
JP (1) JP7368453B2 (https=)
KR (1) KR20210005894A (https=)
CN (1) CN112074541A (https=)
AU (1) AU2019263850A1 (https=)
BR (1) BR112020022371A2 (https=)
CA (1) CA3097916A1 (https=)
IL (1) IL278301B1 (https=)
MX (1) MX2020011588A (https=)
TW (1) TWI784190B (https=)
WO (1) WO2019210848A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016015140A2 (pt) * 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
WO2020151572A1 (en) * 2019-01-23 2020-07-30 Tayu Huaxia Biotech Medical Group Co., Ltd. Anti-pd-l1 diabodies and the use thereof
CN112442126B (zh) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 一种抗人cs1抗原的单克隆抗体及其car-t细胞
CN114728065A (zh) * 2019-11-26 2022-07-08 上海岸迈生物科技有限公司 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
CN116514971B (zh) * 2020-12-10 2023-10-27 北京东方百泰生物科技股份有限公司 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用
WO2022166987A1 (zh) * 2021-02-08 2022-08-11 迈威(上海)生物科技股份有限公司 结合lag-3的抗体及其用途
TW202300516A (zh) * 2021-03-10 2023-01-01 大陸商北京拓界生物醫藥科技有限公司 Pd—1結合蛋白及其醫藥用途
CN118165109A (zh) * 2021-03-31 2024-06-11 美勒斯公司 包含新颖pd-1结合域之多特异性结合部分
CN114989297B (zh) * 2022-06-14 2022-10-25 北京科跃中楷生物技术有限公司 包含辣根过氧化物酶标记的抗体的试剂盒
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK172110B1 (da) 1988-04-15 1997-10-27 Gen Hospital Corp Fremgangsmåde til isolation af mutanter af DNA-sekvenser og anvendelsen heraf til identifikation af celleoverfladeproteiner
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
IL119586A (en) 1996-11-07 2001-09-13 Univ Ramot Discontinuous library of a single biological unit and a method for its preparation
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
EP2322644A1 (en) 2000-06-28 2011-05-18 GlycoFi, Inc. Methods for producing modified glycoproteins
NZ526720A (en) 2000-12-28 2007-11-30 Altus Pharmaceuticals Inc Crystallisation of whole antibodies or fragments thereof, on a large scale and a process allowing an alternative route for delivery of therapeutic antibodies
JP2005503789A (ja) 2001-08-17 2005-02-10 イーライ・リリー・アンド・カンパニー 抗Aβ抗体
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
AU2003294210A1 (en) 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
CN102408483B (zh) 2003-07-15 2016-06-08 安姆根有限公司 作为选择性ngf途径抑制剂的人抗ngf中和抗体
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
US20050250185A1 (en) 2003-12-12 2005-11-10 Murphy Andrew J OGH fusion polypeptides and therapeutic uses thereof
HRP20110657T1 (hr) 2004-03-30 2011-10-31 Glaxo Group Limited Imunoglobulin koji se veže na osm
CN1997382A (zh) 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
AU2006218876A1 (en) 2005-02-28 2006-09-08 Centocor, Inc. Heterodimeric protein binding compositions
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP2468768A3 (en) 2005-07-21 2012-10-31 Abbott Laboratories Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
KR20100058509A (ko) 2007-07-31 2010-06-03 메디뮨 엘엘씨 다중특이적 에피토프 결합 단백질 및 이의 용도
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
DK3153526T3 (da) 2008-01-31 2020-12-14 Inst Nat Sante Rech Med Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
RU2601892C2 (ru) 2008-03-06 2016-11-10 Дженентек, Инк. Комбинированная терапия антагонистами с-мет и egfr
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
BRPI0910482A2 (pt) 2008-04-29 2019-09-24 Abbott Lab imunoglobinas de domínio variável duplo e usos das mesmas
PE20100092A1 (es) 2008-06-03 2010-03-12 Abbott Lab Inmunoglobulina con dominio variable dual y usos de la misma
RU2011101969A (ru) 2008-06-30 2012-08-10 Ново Нордиск А/С (DK) Антитела к человеческому интерлейкину-20
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
JP5616428B2 (ja) 2009-04-07 2014-10-29 ロシュ グリクアート アクチェンゲゼルシャフト 三価の二重特異性抗体
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
EP3492922B1 (en) 2009-09-14 2025-11-05 Icahn School of Medicine at Mount Sinai Methods for characterizing antibody binding affinity and epitope diversity in food allergy
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CN114805583A (zh) 2010-05-27 2022-07-29 根马布股份公司 针对her2的单克隆抗体
MX340556B (es) 2010-08-24 2016-07-14 Roche Glycart Ag Anticuerpos biespecificos activables.
US8962804B2 (en) 2010-10-08 2015-02-24 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
CN103517921B (zh) 2010-12-21 2017-07-18 Abbvie 公司 IL‑1‑α和‑β双特异性双重可变结构域免疫球蛋白及其用途
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
JP2014515598A (ja) 2011-03-10 2014-07-03 エイチシーオー アンティボディ, インク. 二重特異性三鎖抗体様分子
KR102001686B1 (ko) 2011-04-07 2019-07-18 암젠 인크 신규한 egfr 결합 단백질
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
MY169358A (en) 2011-08-23 2019-03-26 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
MX349095B (es) 2011-08-23 2017-07-11 Roche Glycart Ag Moleculas biespecificas de union a antigeno.
PT2802607T (pt) 2012-01-13 2018-01-03 Univ Wuerzburg J Maximilians Complementação funcional bipartida induzida por duplo antigénio
WO2013150043A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
KR102291355B1 (ko) 2012-11-30 2021-08-19 에프. 호프만-라 로슈 아게 Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법
AU2014227638A1 (en) 2013-03-15 2015-09-17 Merck Patent Gmbh Tetravalent bispecific antibodies
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
RU2652880C2 (ru) 2013-04-07 2018-05-03 Дженрикс (Шанхай) Байофармасертикал Ко., Лтд. Антитело против рецептора эпидермального фактора роста
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
KR102089591B1 (ko) 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
CN106029074A (zh) 2013-12-12 2016-10-12 诺华股份有限公司 用于治疗癌症的曲美替尼、帕尼单抗和达拉菲尼组合
BR112016015140A2 (pt) * 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
SG10201900002QA (en) * 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
CN111499753B (zh) 2014-03-03 2022-10-21 高雄医学大学 双功能抗体及其用途
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
CA2947605A1 (en) 2014-05-13 2015-11-19 Bioatla, Llc Conditionally active biological proteins
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
US10092645B2 (en) 2014-06-17 2018-10-09 Medimmune Limited Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy
JP6464255B2 (ja) 2014-08-04 2019-02-06 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性t細胞活性化抗原結合分子
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
WO2016044224A1 (en) 2014-09-15 2016-03-24 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
PL3212226T3 (pl) 2014-10-31 2020-11-02 Ngm Biopharmaceuticals, Inc. Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
WO2016073845A1 (en) 2014-11-07 2016-05-12 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
SI3221357T1 (sl) 2014-11-20 2020-09-30 F. Hoffmann-La Roche Ag Pogoste lahke verige in načini uporabe
GB201500319D0 (en) * 2015-01-09 2015-02-25 Agency Science Tech & Res Anti-PD-L1 antibodies
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
MA43260A (fr) 2015-11-18 2018-09-26 Merck Sharp & Dohme Liants pd1 et/ou lag3
EP3380519A1 (en) 2015-11-23 2018-10-03 Innate Pharma Cd39 vascular isoform targeting agents
WO2017132827A1 (en) 2016-02-02 2017-08-10 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
RU2767329C2 (ru) 2016-02-06 2022-03-17 Эпимаб Биотерапьютикс, Инк. Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
TWI755395B (zh) * 2016-05-13 2022-02-21 美商再生元醫藥公司 抗-pd-1抗體與輻射治療癌症之組合
KR102664891B1 (ko) 2016-06-20 2024-05-13 에프-스타 테라퓨틱스 리미티드 Pd-l1 및 lag-3에 결합하는 결합 분자
CN107840887B (zh) 2016-09-21 2022-03-25 基石药业(苏州)有限公司 一种新的pd-1单克隆抗体
MY203971A (en) 2016-10-13 2024-07-26 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anti-lag-3 antibodies and compositions
US11111305B2 (en) 2017-01-09 2021-09-07 Torch Therapeutics Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex
IL316357A (en) 2017-07-31 2024-12-01 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2019068907A1 (en) 2017-10-06 2019-04-11 Innate Pharma RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73
SG11202002195YA (en) 2017-11-15 2020-04-29 Innate Pharma Potentiating the effect of atp release
AU2020327000A1 (en) 2019-08-08 2022-03-31 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats

Similar Documents

Publication Publication Date Title
JP2021522347A5 (https=)
JP2021534096A5 (https=)
JP2018523493A5 (https=)
JP2021508469A5 (https=)
JP2021522162A5 (https=)
JP2018503380A5 (https=)
JP2021508707A5 (https=)
JP2017535257A5 (https=)
JP2024056687A5 (https=)
RU2018106452A (ru) Поливалетные и полиспецифичные gitr-связывающие слитые белки
JP2018522888A5 (https=)
JP2018507188A5 (https=)
JPWO2019157366A5 (https=)
JP2025092589A5 (https=)
JP2021520832A5 (https=)
JPWO2021104371A5 (https=)
JP2021511387A5 (https=)
JP2021531255A5 (https=)
CN113574069A (zh) 抗pd-l1抗体及其用途
FI3452515T3 (fi) HER-2 sitoutuvia vasta-aineita
KR20240155337A (ko) 항-pd-l2 항체
JPWO2019210848A5 (https=)
JPWO2022042488A5 (https=)
JP2024020436A5 (https=)
JPWO2020081928A5 (https=)